Current and Repurposing Medication for SARS-CoV-2 Infection
Keywords:
SARS-CoV-2, COVID-19, Repurposing agents, Antiviral, RemdesivirAbstract
In the crisis of COVID-19 pandemic, there is no specific agent to treat SARS-CoV-2 infection. Repurposing medication can be an alternative agent. Remdesivir is the first antiviral drug that has been approved for COVID-19 treatment whereas lopinavir/ritonavir and hydroxychloroquine, which was early used in SARS-CoV-2 widespread, are against by well-known guidelines due to lack of efficacy and potential toxicity. Corticosteroids are an essential supportive care in COVID-19 patient with severe disease to reduce lung inflammation. Favipiravir may have a potential benefit for COVID-19 patient, but the data is still uncertain. Ivermectin, an antihelmintic agent, may be used against SARS-CoV-2 but further studies are needed. Immunomodulatory such as tocilizumab in combination with dexamethasone can be used for reducing inflammatory storm during severe COVID-19. Baricitinib is considered as an alternative agent for patients with COVID-19. Repurposing drugs with possible mechanism against SARS-CoV-2 are essential key to combat with SARS-CoV-2 during the specific medications under investigation.
Downloads
References
WHO Coronavirus (COVID-19) Overview. World Health Organization. https://covid19.who.int/. Updated June 27, 2021. Accessed June 28, 2021.
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12(3):7423.
Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, Jafari D, Mirzabeigi P. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol. 2021;895:173890.
Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501-508.
Report on the Deliberation Results: Avigan. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. https://www.pmda.go.jp/files/000210319.pdf. Published 2014. Accessed July 3, 2021.
Thailand Clinical Practice Guideline (update May 6, 2021). Department of Medical Services. https://covid19.dms.go.th/backend/Content/Content_FIle/Bandner_(Big)/Attach/25640507102416AM_CPG_COVID_v.14_n_20210506.2.pdf. Updated May 6, 2021. Accessed July 3, 2021.
Swift R. Fujifilm starts new late-phase trial of Avigan in Japan for COVID-19 patients. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/fujifilm-starts-new-late-phase-trial-avigan-japan-covid-19-patients-2021-04-21. Published April 21, 2021. Accessed August 8, 2021.
Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management. Updated June 25, 2021. Accessed July 3, 2021.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19 treatment guidelines.nih.gov. Updated June 17, 2021. Accessed July 3, 2021.
Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing, China). 2020;6(10):1192-1198.
Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020. doi: 10.1101/2020.03.17.20037432.
Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141.
Barlow A, Landolf KM, Barlow B, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020;40(5):416-437.
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020;34(1).
Humeniuk R, Mathias A, Cao H, et al. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci. 2020;13(5):896-906.
Marra F, Smolders EJ, El-Sherif O, et al. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs R D. 2021;21(1):9-27.
Thakare S, Gandhi C, Modi T, et al. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep. 2021;6(1):206-210.
Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826.
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048-1057.
Shrestha DB, Budhathoki P, Syed NI, Rawal E, Raut S, Khadka S. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. Life Sci. 2021;264:118663.
Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):25489.
Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020;131:110668.
Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19). Ann Intern Med. 2020;173(8):670-672.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-1352.
Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021;73(3):736-749.
Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4):434-460.
Padhi S, Pati A, Panda AK. Effect of ivermectin in the treatment of COVID-19: A trial sequential analysis highlighted the requirement of additional randomized controlled trials. Clin Infect Dis. 2021;692.
Banno M, Tsujimoto Y, Ishikane M. Need for more randomized controlled trials with rigorous methodology to confirm that ivermectin is not a viable option for the treatment of coronavirus disease. Clin Infect Dis. 2021;689.
Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-2040.
Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418.
Tocilizumab. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/. Updated 2021. Accessed August 7, 2021.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.
Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502.
Baricitinib. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/. Updated 2021. Accessed August 7, 2021.
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795-807.
Romanou V, Koukaki E, Chantziara V, et al. Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? J Pers Med. 2021;11(6):556.
Johns M, George S, Taburyanskaya M, Poon YK. A Review of the Evidence for Corticosteroids in COVID-19. J Pharm Pract. 2021;897190021998502.
Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954-963.
Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829-840.
Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329.
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276.
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.
Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-1341.
Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med. 2021;9(1):8.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
